You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia

http://dx.doi.org/10.1136/ebmh.9.2.48

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005;62:1196–204.OpenUrlCrossRefPubMedWeb of Science

    Q Does adding sarcosine or D-serine to risperidone improve symptoms in people with acute phase schizophrenia?

    METHODS

    Embedded ImageDesign:

    Randomised controlled trial.

    Embedded ImageAllocation:

    Concealed.

    Embedded ImageBlinding:

    Double blind.

    Embedded ImageFollow up period:

    Six weeks.

    Embedded ImageSetting:

    Two hospital inpatient units, Taiwan, from January 2000 to July 2003.

    Embedded ImagePatients:

    Sixty five people aged 18–60 years with acute exacerbation of DSM-IV schizophrenia (45% female). Exclusions: baseline Positive and Negative Syndrome Scale (PANSS) total score <60; abnormal urine, blood, biochemical, or electrocardiography results; substance abuse or dependence; smoker; received atypical antipsychotic; contrainidication to antipsychotics; or received depot antipsychotic in previous six months.

    Embedded ImageIntervention:

    D-serine (2 g/day) plus risperidone (titrated to 6 mg/day); sarcosine (2 g/day) plus risperidone; placebo plus …

    View Full Text

    Footnotes

    • For correspondence: Guochuan E Tsai, Department of Psychiatry, Harbor-UCLA Medical Center, 1000 W Carson Street, Torrance, CA 90509, USA; etsai{at}labiomed.org

    • Sources of funding: National Science Council, National Health Research Institutes and China Medical University, Taiwan, and the National Alliance for Research on Schizophrenia and National Institute of Mental Health, USA.